Development of an oral prime-boost strategy to elicit broadly neutralizing antibodies against HIV-1

被引:39
作者
Devico, AL
Fouts, TR
Shata, MT
Kamin-Lewis, R
Lewis, GK
Hone, DM
机构
[1] Univ Maryland, Inst Biotechnol, Inst Human Virol, Div Vaccine Res, Baltimore, MD 21201 USA
[2] Univ Maryland, Sch Med, Dept Microbiol & Immunol, Baltimore, MD 21201 USA
关键词
prime-boost strategy; neutralizing antibodies; HIV-1;
D O I
10.1016/S0264-410X(02)00080-4
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Given the increasing incidence of HIV-1 infection world-wide, an affordable, effective vaccine is probably the only way that this virus will be contained. Accordingly. our group is developing an oral prime-boost strategy with the primary goal of eliciting broadly neutralizing antibodies against HIV-1 to provide sterilizing immunity for this virus. Our secondary goal is to elicit broadly cross-reactive anti-viral CD8(+) T cells by this strategy to blunt any breakthrough infections that occur after vaccination of individuals who fail to develop sterilizing immunity. This article describes our progress in the use of the live attenuated intracellular bacteria, Salmonella and Shigella. as oral delivery vehicles for DNA vaccines and the development of conformationally constrained HIV-1 Env immunogens that elicit broadly neutralizing antibodies. (C) 2002 Published by Elsevier Science Ltd.
引用
收藏
页码:1968 / 1974
页数:7
相关论文
共 83 条
  • [51] Genetic subtypes, humoral immunity, and human immunodeficiency virus type 1 vaccine development
    Moore, JP
    Parren, PWHI
    Burton, DR
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (13) : 5721 - 5729
  • [52] MORIKAWA Y, 1990, J VIROL METHODS, V29, P105, DOI 10.1016/0166-0934(90)90013-6
  • [53] Murphey-Corb M, 1999, J IMMUNOL, V162, P540
  • [54] Energetics of the HIV gp120-CD4 binding reaction
    Myszka, DG
    Sweet, RW
    Hensley, P
    Brigham-Burke, M
    Kwong, PD
    Hendrickson, WA
    Wyatt, R
    Sodroski, J
    Doyle, ML
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (16) : 9026 - 9031
  • [55] Further characterization of Delta aroA Delta virG Shigella flexneri 2a strain CVD 1203 as a Mucosal shigella vaccine and as a live-vector vaccine for delivering antigens of enterotoxigenic Escherichia coli
    Noriega, FR
    Losonsky, G
    Wang, JY
    Formal, SB
    Levine, MM
    [J]. INFECTION AND IMMUNITY, 1996, 64 (01) : 23 - 27
  • [56] Engineered Delta guaB-A Delta virG Shigella flexneri 2a strain CVD 1205: Construction, safety, immunogenicity, and potential efficacy as a mucosal vaccine
    Noriega, FR
    Losonsky, G
    Lauderbaugh, C
    Liao, FM
    Wang, JY
    Levine, MM
    [J]. INFECTION AND IMMUNITY, 1996, 64 (08) : 3055 - 3061
  • [57] Gene transfer in dendritic cells, induced by oral DNA vaccination with Salmonella typhimurium, results in protective immunity against a murine fibrosarcoma
    Paglia, P
    Medina, E
    Arioli, I
    Guzman, CA
    Colombo, MP
    [J]. BLOOD, 1998, 92 (09) : 3172 - 3176
  • [58] Parren PWHI, 1999, AIDS, V13, pS137
  • [59] Pascual D W, 1997, Behring Inst Mitt, P143
  • [60] Attenuated ΔguaBA Salmonella typhi vaccine strain CVD 915 as a live vector utilizing prokaryotic or eukaryotic expression systems to deliver foreign antigens and elicit immune responses
    Pasetti, MF
    Anderson, RJ
    Noriega, FR
    Levine, MM
    Sztein, MB
    [J]. CLINICAL IMMUNOLOGY, 1999, 92 (01) : 76 - 89